Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents
Journal of Diabetes and its Complications, 05/17/2012
Sakharova OV et al. - In type 2 diabetes patients failing oral anti-hyperglycemic drugs (OADs) therapy, an initial insulin regimen of twice daily premixed insulin results in significantly improved post-prandial glucose levels as well as a reduction in a precursor of AGEs. The effect of these two initial insulin regimens on long-term diabetic complications requires further study.
This was a 6-month, open-label, single-center study using a cross-over design.
14 subjects were randomized to one of two protocols: once daily insulin glargine or twice-daily 75%/25% neutral protamine lispro/lispro mix.
At 12 weeks, the subjects were crossed-over to the opposite protocol.
During each period, insulin doses were titrated to target fasting blood glucose of 90–110mg/dL.
At baseline and after the two 12-week treatment periods, subjects were studied in the Clinical Research Center; they consumed three liquid mixed isocaloric meals at 4-h intervals, and glucose, free fatty acids (FFA), lipids, and α-dicarbonyls (3-deoxyglucosone [3-DG] and methylglyoxal [MG]) were measured before and after each meal.
Patient data were analyzed in the context of their assigned insulin strategy groups.
Both insulin regimens led to a significant improvement in glycemic profiles, including fasting glucose and HbA1c, compared to baseline.
However, mean post-prandial glucose was lower with lispro mix than with glargine (153±36 vs. 199±49 mg/dL, respectively; P=0.001).
Likewise, there was a reduction in both fasting (48±13 vs. 57±19, P=0.047) and post-prandial (53±19 vs. 63±23; P=0.007) 3DG levels with lispro mix as compared to glargine.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.